Please ensure Javascript is enabled for purposes of website accessibility

Top Marijuana Stocks to Buy in 2017

By Keith Speights – Updated May 24, 2017 at 3:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's why GW Pharmaceuticals, Corbus Pharmaceuticals, and Insys Therapeutics rank among the top marijuana stocks to buy for the New Year.

Risky, speculative, uncertain. 

All these words apply to investing in marijuana stocks. But if you're looking to buy marijuana stocks in the New Year, GW Pharmaceuticals (GWPH), Corbus Pharmaceuticals Holdings (CRBP 1.88%), and Insys Therapeutics (INSY) might be your best choices. Here's why these three rank among the top marijuana stocks to buy in 2017.

"2017" against a sunset, with a person as the "1"

Image source: Getty Images.

Promising epilepsy treatment

There has been one success after another for GW Pharmaceuticals' cannabidiol drug Epidiolex. In March, the biotech announced positive results from a late-stage study of the drug in treating seizures associated with Dravet syndrome, a rare form of epilepsy that occurs in infants. Three months later came news of more positive results from a study of Epidiolex in treating seizures associated with Lennox-Gastaut syndrome (LGS), a rare form of epilepsy that begins in childhood.

They say that bad news comes in threes, but good news might also. In September, GW Pharmaceuticals announced positive results from a third late-stage study of Epidiolex. This study also evaluated the drug in treating LGS seizures. GW Pharmaceuticals expects to file for regulatory approval in the U.S. in the first half of 2017, based on these clinical studies.

If Epidiolex wins approval, some analysts think the drug could achieve peak annual sales of around $3 billion. GW Pharmaceuticals' market cap currently stands at roughly that same amount. Should the company's epilepsy drug prove to be as successful as the optimistic projections, there's no question that GW's stock will soar.

Be aware, however, that other analysts are more pessimistic. Lower peak sales estimates for Epidiolex range from $300 million to $800 million. GW Pharmaceuticals' shares would have plenty of upward potential at the upper end of that range, but not at the low end. Of course, it will be quite a while before we know which estimate is most accurate. In the meantime, I expect bullish sentiment will prevail for GW Pharmaceuticals. 

Potential catalysts ahead

Corbus Pharmaceuticals emerged as one of the biggest marijuana stock winners of 2016. The share price of the clinical-stage biotech quadrupled this year with high expectations for its oral endocannabinoid-mimetic drug Resunab.

While many investors were excited about Resunab's prospects, there was also a great deal of skepticism about whether or not the drug would prove successful in a mid-stage clinical study for treating systemic sclerosis, a chronic autoimmune rheumatic disease. Corbus answered the skeptics in November when the company announced positive results from that study.

In the mid-stage study, Resunab achieved a Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score of 33% at week 16, versus 0% for placebo. To put that into perspective, a CRISS score of 20% is considered a medically meaningful improvement. Corbus CEO Yuval Cohen gushed that the positive results exceeded the company's expectations.

Another potential catalyst for Corbus is just around the corner. The company expects to report top-line results from a mid-stage study of Resunab in treating cystic fibrosis in the first quarter of 2017. Corbus also plans to announce results from a mid-stage dermatomyositis study in the third quarter of 2017.

It's possible that pessimism about Resunab's prospects could prove warranted when these results are announced. However, if Corbus pulls off a surprise or two like it did with the systemic sclerosis study results, this marijuana stock should skyrocket yet again.

Worst to first?

A picture is supposed to be worth a thousand words, so I'll let the following chart tell the story for Insys Therapeutics in 2016:

INSY Chart

INSY data by YCharts.

This dismal performance made Insys one of the worst marijuana stocks of the year. Insys' woes relate primarily to rapidly declining sales for its lead drug, Subsys. However, better days could be on the way.

In July, Insys received good news for its first cannabinoid candidate, Syndros. The U.S. Food and Drug Administration (FDA) approved the drug as a treatment for anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional treatments. That good news hasn't translated to financial success for Insys yet, however, because Syndros is still waiting to be scheduled by the U.S. Drug Enforcement Administration.

Insys should launch Syndros in the U.S. next year. Piper Jaffray analyst David Amsellem estimates the drug could reach peak annual sales of $300 million to $400 million. Considering that Insys' market cap now is only around $800 million, a successful kick-off for Syndros in 2017 could be just what the company needs to transition from one of the worst marijuana stocks to one of the best.

Marijuana stocks have been hotter than a firecracker lit at both ends. Are they the right investment for you?

Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

INSYS Therapeutics Stock Quote
INSYS Therapeutics
INSY
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH
Corbus Pharmaceuticals Holdings, Inc. Stock Quote
Corbus Pharmaceuticals Holdings, Inc.
CRBP
$0.17 (1.88%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.